Cargando…
Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to a...
Autores principales: | Mirzania, Mehrzad, Khalili, Sedigheh, Hasanpoor, Akbar, Shamshiri, Ahmad Reza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003443/ https://www.ncbi.nlm.nih.gov/pubmed/24800039 |
Ejemplares similares
-
Mononeuritis multiplex in acquired amegakaryocytic thrombocytopenia
por: Khan, Firosh, et al.
Publicado: (2015) -
Acquired amegakaryocytic thrombocytopenia after durvalumab
administration
por: Suyama, Takahiro, et al.
Publicado: (2021) -
Acquired Amegakaryocytic Thrombocytopenia Progressing to Aplastic Anaemia
por: Hussain, Syed Ather, et al.
Publicado: (2022) -
The name counts: the case of 'congenital amegakaryocytic thrombocytopenia'
por: Balduini, Carlo L.
Publicado: (2022) -
Congenital Amegakaryocytic Thrombocytopenia: A Brief Review of the Literature
por: Al-Qahtani, Fatma S.
Publicado: (2010)